Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Sponsor
Medicago (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04636697
Collaborator
(none)
30,918
Enrollment
91
Locations
2
Arms
17.3
Anticipated Duration (Months)
339.8
Patients Per Site
19.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.

The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared to placebo.

Subjects will be followed for safety and immunogenicity for a period of 12 months after the last vaccination.

Condition or DiseaseIntervention/TreatmentPhase
  • Drug: Intramuscular injection
  • Biological: Intramuscular vaccine
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30918 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Observer-blind
Primary Purpose:
Prevention
Official Title:
Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older
Actual Study Start Date :
Nov 19, 2020
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Apr 30, 2022

Arms and Interventions

ArmIntervention/Treatment
Placebo Comparator: Placebo

Placebo (0.5 mL)

Drug: Intramuscular injection
Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

Experimental: 3.75 µg of CoVLP Vaccine adjuvanted

3.75 µg of CoVLP adjuvanted vaccine with AS03 adjuvant (0.5 mL)

Biological: Intramuscular vaccine
Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)

Outcome Measures

Primary Outcome Measures

  1. Phase 2 portion: Immediate adverse event (AEs) [30 minutes]

    Percentage, intensity, and relationship to vaccination of immediate AEs

  2. Phase 2 portion: Solicited local and systemic adverse events (AEs) [7 days]

    Percentage, intensity, and relationship to vaccination of solicited local and systemic AEs

  3. Phase 2 portion: Unsolicited adverse events (AEs) [21 days]

    Percentage, intensity, and relationship of unsolicited AEs

  4. Phase 2 portion: Number of subjects with normal and abnormal clinically significant urine values [3 days]

    Number of subjects with normal and abnormal clinically significant urine values

  5. Phase 2 portion: Number of subjects with normal and abnormal clinically significant haematological values [3 days]

    Number of subjects with normal and abnormal clinically significant haematological values

  6. Phase 2 portion: Number of subjects with normal and abnormal clinically significant biochemical values [3 days]

    Number of subjects with normal and abnormal clinically significant biochemical values

  7. Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant urine values [3 days]

    Percentage of subjects with normal and abnormal clinically significant urine values

  8. Phase 2 portion: Percentage of subjects with normal and abnormal clinically significant haematological values [3 days]

    Percentage of subjects with normal and abnormal clinically significant haematological values

  9. Phase 2 portion: Percentage of subjects with normal and abnormal clinically biochemical values [3 days]

    Percentage of subjects with normal and abnormal clinically biochemical values

  10. Phase 2 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths [21 days]

    Percentage of SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VED), and deaths

  11. Phase 2 portion: Neutralizing antibody (Nab assay) response [Day 21]

    Nab response induced in each Study Population against the SARS-CoV-2 virus

  12. Phase 2 portion: Neutralizing antibody (Nab assay) response [Day 42]

    Nab response induced in each Study Population against the SARS-CoV-2 virus

  13. Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response [Day 21]

    Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 , as measured by IFN-γ ELISpot

  14. Phase 2 portion:Specific Th1 cell-mediated immunity (CMI) response [Day 42]

    Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 , as measured by IFN-γ ELISpot

  15. Phase 3 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection [Day 28 and after]

    First occurrence, in a subject, of laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection

Secondary Outcome Measures

  1. Phase 2 portion: Solicited local and systemic AEs (populations 1 and 2) [7 days]

    Relative percentage of solicited local and systemic AEs following each vaccine administration between the healthy adults (Study Population #1) and the healthy elderly population (Study Population #2, each age strata);

  2. Phase 2 portion: Solicited local and systemic AEs (populations 1, 2 and 3) [7 days]

    Relative percentage of solicited local and systemic AEs by intensity grades for seven days following each vaccine administration between the healthy adults (Study Population #1) and the healthy elderly adults (Study Population #2) combined and the adults with significant comorbidities (Study Population #3)

  3. Phase 2 portion: Serious adverse events (SAEs), medically attended adverse events (MAAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths [Day 43 to 386]

    Percentage of SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VED), and deaths

  4. Phase 3 portion: Immediate adverse event (AEs) [30 minutes]

    Percentage, intensity, and relationship to vaccination of immediate AEs

  5. Phase 3 portion: Solicited local and systemic AEs [7 days]

    Percentage, intensity, and relationship to vaccination of solicited local and systemic AEs

  6. Phase 3 portion: Unsolicited adverse events (AEs) [21 days]

    Percentage, intensity, and relationship of unsolicited AEs

  7. Phase 3 portion: Serious adverse events (SAEs), adverse events (AEs) leading to withdrawal, adverse event of special interest (AESI) (including vaccine-enhanced disease) and deaths [Day 0 to 386]

    Percentage of SAEs, MAAEs, AEs leading to withdrawal, AESIs (including VED), and deaths

  8. Phase 2 portion: Neutralizing antibody Geometric mean tiers (GMT) response (populations 1 and 2) [21 days]

    Relative neutralizing antibody response between the healthy adults (Study Population #1) and the healthy elderly population (Study Population #2; each age strata) will be analyzed using the Following parameter: Geometric mean tiers (GMT)

  9. Phase 2 portion: Neutralizing antibody Geometric mean tiers (GMT) response (populations 1, 2 and 3) [21 days]

    • Relative neutralizing antibody response between the healthy adults (Study Population #1) and the healthy elderly adults (Study Population #2) combined and the adults with significant comorbidities (Study Population #3) will be analyzed using the Following parameter: Geometric mean tiers (GMT)

  10. Phase 2 portion: Neutralizing antibody (Nab assay) response [Day 128]

    Persistence of the Nab antibody response induced in each Study Population against the SARS-CoV-2 virus

  11. Phase 2 portion: Neutralizing antibody (Nab assay) response [Day 201]

    Persistence of the Nab antibody response induced in each Study Population against the SARS-CoV-2 virus

  12. Phase 2 portion: Neutralizing antibody (Nab assay) response [Day 386]

    Persistence of the Nab antibody response induced in each Study Population against the SARS-CoV-2 virus

  13. Phase 2 portion: Specific antibody (IgG) response [Day 128]

    Specific antibody response induced in each Study Population against the SARS-CoV-2 virus will be measured by the total IgG levels

  14. Phase 2 portion: Specific antibody (IgG) response [Day 201]

    Specific antibody response induced in each Study Population against the SARS-CoV-2 virus will be measured by the total IgG levels

  15. Phase 2 portion: Specific antibody (IgG) response [Day 386]

    Specific antibody response induced in each Study Population against the SARS-CoV-2 virus will be measured by the total IgG levels

  16. Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 21]

    The ratio of neutralizing antibody titers:IgG ELISA antibody titers

  17. Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 42]

    The ratio of neutralizing antibody titers:IgG ELISA antibody titers

  18. Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 128]

    The ratio of neutralizing antibody titers:IgG ELISA antibody titers

  19. Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 201]

    The ratio of neutralizing antibody titers:IgG ELISA antibody titers

  20. Phase 2 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 386]

    The ratio of neutralizing antibody titers:IgG ELISA antibody titers

  21. Phase 2 portion: Specific Th1 cell-mediated immunity (CMI) response [Day 201]

    Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot

  22. Phase 2 portion: Specific Th1 cell-mediated immunity (CMI) response [Day 386]

    Specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot

  23. Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response [Day 21]

    Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)

  24. Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response [Day 42]

    Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)

  25. Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response [Day 201]

    Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)

  26. Phase 2 portion: Specific Th2 cell-mediated immunity (CMI) response [Day 386]

    Specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)

  27. Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response [Day 21]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)

  28. Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response [Day 21]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate

  29. Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response [Day 21]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)

  30. Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response [Day 42]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)

  31. Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response [Day 42]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate

  32. Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response [Day 42]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)

  33. Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response [Day 201]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)

  34. Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) [Day 201]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)

  35. Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response [Day 201]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate

  36. Phase 3 portion: Neutralizing antibody Geometric mean fold rise (GMFR) response [Day 386]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean fold rise (GMFR)

  37. Phase 3 portion: Neutralizing antibody Geometric mean titers (GMT) response [Day 386]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Geometric mean titers (GMT)

  38. Phase 3 portion: Neutralizing antibody Seroconversion (SC) rate response [Day 386]

    In a subset of subjects, Nab antibody response induced in each Study Population against the SARS-CoV-2 virus analyzed, using the following parameters: Seroconversion (SC) rate

  39. Phase 3 portion: Specific antibody (IgG) response [Day 21]

    In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels

  40. Phase 3 portion: Specific antibody (IgG) response [Day 42]

    In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels

  41. Phase 3 portion: Specific antibody (IgG) response [Day 201]

    In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels

  42. Phase 3 portion: Specific antibody (IgG) response [Day 386]

    In a subset of subjects, specific antibody response induced in each Study Population against the SARS-CoV-2 virus measured by the total IgG levels

  43. Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 21]

    In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers

  44. Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 42]

    In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers

  45. Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 201]

    In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers

  46. Phase 3 portion: Neutralizing antibody titers: IgG ELISA antibody titers [Day 386]

    In a subset of subjects, the ratio of neutralizing antibody titers:IgG ELISA antibody titers

  47. Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response [Day 21]

    In a subset of subjects, specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot

  48. Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response [Day 42]

    In a subset of subjects, specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot

  49. Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response [Day 201]

    In a subset of subjects, specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot

  50. Phase 3 portion: Specific Th1 cell-mediated immunity (CMI) response [Day 386]

    In a subset of subjects, specific Th1 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IFN-γ ELISpot

  51. Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response [Day 21]

    In a subset of subjects, specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)

  52. Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response [Day 42]

    In a subset of subjects, specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)

  53. Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response [Day 201]

    In a subset of subjects, specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)

  54. Phase 3 portion: Specific Th2 cell-mediated immunity (CMI) response [Day 386]

    In a subset of subjects, specific Th2 CMI response induced in each Study Population against the SARS-CoV-2 virus; as measured by IL-4 (ELISpot)

  55. Phase 2 portion: Laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection [Day 28 to 386]

    First occurrence, in a subject, of laboratory-confirmed (virologic method) symptomatic SARS-CoV-2 infection

  56. Phase 2 portion: Severe COVID-19 disease [Day 28 to 386]

    Percentage of severe COVID-19 disease

  57. Phase 3 portion: Severe COVID-19 disease [Day 28 to 386]

    Percentage of severe COVID-19 disease

  58. Phase 3 portion: COVID-19-related symptoms in virologically-confirmed cases [through efficacy analysis, approximately 4 months]

    Percentage and intensity of COVID-19-related symptoms

  59. Phase 3 portion: Laboratory-confirmed asymptomatic SARS-CoV-2 infection [Day 201]

    Percentage of laboratory-confirmed asymptomatic SARS-CoV-2 infection: confirmed by the ELISA method for the N protein

  60. Phase 3 portion: Laboratory-confirmed symptomatic SARS-CoV-2 infection [through efficacy analysis, approximately 4 months]

    First occurence, in a subject, of laboratory-confirmed symptomatic SARS-CoV-2 infection: virologic method

  61. Phase 3 portion: Laboratory-confirmed symptomatic SARS-CoV-2 infection [Day 0 to 21]

    First occurence, in a subject, of laboratory-confirmed symptomatic SARS-CoV-2 infection: virologic method

  62. Phase 3 portion: Laboratory-confirmed symptomatic SARS-CoV-2 infection [Day 21 to 28]

    First occurence, in a subject, of laboratory-confirmed symptomatic SARS-CoV-2 infection: virologic method

  63. Phase 3 portion: Viral shedding after SARS-CoV-2 infection [through efficacy analysis, approximately 4 months]

    Duration and intensity of viral shedding after SARS-CoV-2 infection

  64. Phase 3 portion: Laboratory-confirmed symptomatic SARS-CoV-2 infection (by strain) [through efficacy analysis, approximately 4 months]

    First occurrence, in a subject, of laboratory-confirmed symptomatic SARS-CoV-2 infection by strain: virologic method

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  1. Subjects must have read, understood, and signed the informed consent form (ICF) prior to participating in the study; subjects must also complete study-related procedures and the subjects must communicate with the study staff at visits and by phone during the study;

  2. At the Screening visit (Visit 1), male and female subjects must be:

  • Study Populations #1: 18 to 64 (has not yet had his/her 65th birthday) years of age, inclusive;

  • Study Population #2: 65 years of age or older;

  • Study Population #3: 18 years of age or older;

  1. At Screening (Visit 1) and Vaccination (Visit 2), subject must have a body mass index (BMI) of:

• Study Populations #1 and #2: ≥ 18.5 and < 30 kg/m2;

  1. Subjects are considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study;

  2. Study Population #1: Subjects must be in good general health prior to study participation, with no clinically relevant abnormalities that could jeopardize subject safety or interfere with study assessments, as determined by medical history, physical examination, and vital signs. Investigator discretion will be permitted with this inclusion criterion;

All regions except Canada: Note: Subjects with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator's judgment that must be documented in the source documents, the condition is unlikely to confound the results of the study or pose additional risk to the subject by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease three months prior to vaccination. Based on the Investigator's judgment, a subject with more recent stabilization of a disease could also be eligible.

  1. Study Populations #1 and #3: Female subjects of childbearing potential must have a negative serum pregnancy test result at Screening (Visit 1 for the Phase 2 portion) and/or a negative urine pregnancy test result at Vaccination (Visit 2 for the Phase 2 portion; Visit 1 for the Phase 3 portion):
Non-childbearing females are defined as:
  • Surgically-sterile (defined as bilateral tubal ligation, hysterectomy or bilateral oophorectomy performed more than one month prior to the first study vaccination); or

  • Post-menopausal (absence of menses for 12 consecutive months and age consistent with natural cessation of ovulation);

  1. Study Populations #1 and #3: Female subjects of childbearing potential must use an effective method of contraception for one month prior to vaccination (Visit 2) and agree to continue employing highly effective birth control measures for at least one month after the last study vaccination (or in the case of early termination, she must not plan to become pregnant for at least one month after her last study vaccination).

The following relationship or methods of contraception are considered to be highly effective:

  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

  • Oral;

  • Intravaginal;

  • Transdermal;

  • Progestogen-only hormonal contraception associated with inhibition of ovulation:

  • Oral;

  • Injectable;

  • Implantable;

  • Intra-uterine device with or without hormonal release;

  • Credible self-reported history of heterosexual vaginal intercourse abstinence prior to and for at least one month after the last study vaccination. Abstinent subjects who are ovulating should be asked what method(s) they would use should their circumstances change, and subjects without a well-defined plan should be excluded;

  • Female partner;

  • All regions except the US: Vasectomised partner, provided that this partner is the sole sexual partner of the study participant and that the vasectomised partner has received a medical assessment of the surgical success;

  • Bilateral tubal ligation.

  1. Study Population #2: Subjects must be non-institutionalized (e.g. not living in rehabilitation centres or old-age homes; living in an elderly community is acceptable) and have no acute or evolving medical problems prior to study participation and no clinically relevant abnormalities that could jeopardize subject safety or interfere with study assessments, as assessed by the Principal Investigator or sub-Investigator (thereafter referred as Investigator) and determined by medical history, physical examination, serology (only for the Phase 2 portion), clinical chemistry and haematology tests (only for the Phase 2 portion), urinalysis (only for the Phase 2 portion), and vital signs. Investigator discretion will be permitted with this inclusion criterion.

All regions except Canada: Note: Subjects with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator's judgment that must be documented in the source documents, the condition is unlikely to confound the results of the study or pose additional risk to the subject by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease three months prior to vaccination. Based on the Investigator's judgment and documented in source documentation, a subject with more recent stabilization of a disease could also be eligible;

  1. Study Population #3: Subjects must have one or more co-morbid conditions that puts them at higher risk for severe COVID-19 disease. These comorbidities include but are not limited to obesity, hypertension, type 1 or type 2 diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular diseases, chronic kidney diseases, or be immunocompromised persons (e.g., treatment-controlled HIV infection, organ transplant recipients, or patients receiving cancer chemotherapy). Investigator discretion will be permitted with this inclusion criterion.
Exclusion criteria:
  1. Study Populations #1 and #2: According to the Investigator's opinion, significant acute or chronic, uncontrolled medical or neuropsychiatric illness.

Acute disease is defined as presence of any moderate or severe acute illness with or without a fever within 48 hours prior to the Screening (Visit 1) and/or Vaccination visit (Visit 2). 'Uncontrolled' is defined as:

  • Requiring a new medical or surgical treatment during the three months prior to study vaccine administration;

  • Requiring any significant change in a chronic medication (i.e. drug, dose, frequency) during the three months prior to study vaccine administration due to uncontrolled symptoms or drug toxicity unless the innocuous nature of the medication change meets the criteria outlined in inclusion criterion no. 5 (Study Population #1) or no. 8 (Study Population #2) and is appropriately justified and documented by the Investigator.

Investigator discretion is permitted with this exclusion criterion and must be carefully and fully documented in the source documents;

  1. Study Populations #1 and #2: Any chronic medical condition associated with elevated risk of severe outcomes of COVID-19, including obesity, diabetes (type 1 or type 2), significant cardiovascular or respiratory diseases including asthma, chronic renal failure, disorders of bleeding/coagulation, chronic inflammatory or autoimmune conditions, immunosuppressive conditions (including HIV), and hypertension;

  2. Study Populations #1 and #2: Any confirmed or suspected current immunosuppressive condition or immunodeficiency, including cancer, human immunodeficiency virus (HIV), hepatitis B or C infection (subjects with a history of cured hepatitis B or C infection without any signs of immunodeficiency at present time are allowed). Investigator discretion is permitted with this exclusion criterion;

  3. Study Populations #1 and #2: Current autoimmune disease (such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis or narcolepsy). Investigator discretion is permitted with this exclusion criterion, and subjects may be eligible to participate with appropriate written justification in the source document (i.e. subjects with a history of autoimmune disease who are disease-free without treatment for three years or more, or on stable thyroid replacement therapy, mild psoriasis [i.e. a small number of minor plaques requiring no systemic treatment], etc.);

  4. Study Populations #1 and #2: Administration of any medication or treatment that may alter the vaccine immune responses, such as:

  • Systemic glucocorticoids at a dose exceeding 10 mg of prednisone (or equivalent) per day for more than seven consecutive days or for 10 or more days in total, within one month prior to the Vaccination visit (Visit 2). Inhaled, nasal, ophthalmic, dermatological, and other topical glucocorticoids are permitted;

  • Cytotoxic, antineoplastic, or immunosuppressant drugs - within 36 months prior to Vaccination (Visit 2);

  • Any immunoglobulin preparations or blood products, blood transfusion - within 6 months prior to Vaccination (Visit 2);

  1. Study Population #3: Acute disease defined as presence of any moderate or severe acute illness with or without a fever within 48 hours prior to the Screening (Visit 1) and/or Vaccination visit (Visit 2);

  2. Administration of any vaccine within 14 days prior to Vaccination (Visit 2); planned administration of any vaccine during the study (up to Day 28 of the study). Immunization on an emergency basis during the study will be evaluated on case-by-case basis by the Investigator;

  3. Administration of any other SARS-CoV-2 / COVID-19, or other experimental coronavirus vaccine at any time prior to or during the study;

  4. History of virologically-confirmed COVID-19;

  5. Use of any investigational or non-registered product within 30 days or 5 half-lives, whichever is longer, prior to Vaccination (Visit 2) or planned use during the study period. Subjects who are in a prolonged post-administration observation period of another investigational or marketed drug clinical study, for which there is no ongoing exposure to the investigational or marketed product and all scheduled on-site visits are completed, will be allowed to take part in this study, if all other eligibility criteria are met;

  6. Have a rash, dermatological condition, tattoos, muscle mass, or any other abnormalities at injection site that may interfere with injection site reaction rating. Investigator discretion will be permitted with this exclusion criterion;

  7. Use of any prescription antiviral drugs with the intention of COVID-19 prophylaxis, including those that are thought to be effective for prevention of COVID-19 but have not been licensed for this indication, within one month prior to Vaccination (Visit 2);

  8. For the Phase 2 portion of the study only: Use of prophylactic medications (e.g. antihistamines [H1 receptor antagonists], nonsteroidal anti-inflammatory drugs [NSAIDs], systemic and topical glucocorticoids, non-opioid and opioid analgesics) within 24 hours prior to the Vaccination (Visit 2) to prevent or pre-empt symptoms due to vaccination;

  9. History of a serious allergic response to any of the constituents of CoVLP including AS03;

  10. History of a documented anaphylactic reactions to plants or plant components (including tobacco, fruits and nuts);

  11. Personal or family history of narcolepsy;

  12. Subjects with a history of Guillain-Barré Syndrome;

  13. Study Populations #1 and #3: Any female subject who has a positive or doubtful pregnancy test result prior to vaccination or who is lactating;

  14. Subjects identified as an Investigator or employee of the Investigator or clinical site with direct involvement in the proposed study, or identified as an immediate family member (i.e. parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study, or any employees of Medicago.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Achieve Clinical Research, LLC dba Accel Research SitesBirminghamAlabamaUnited States35216
2Fiel Family and Sports Medicine/CCTTempeArizonaUnited States85283
3Hope Clinical ResearchCanoga ParkCaliforniaUnited States91303
4CNS NetworkGarden GroveCaliforniaUnited States92845
5Long Beach Clinical Trial Services Inc.Long BeachCaliforniaUnited States90806-3221
6Pharmacology Research InstituteNewport BeachCaliforniaUnited States92660
7Wr-McCr, LlcSan DiegoCaliforniaUnited States92108
8Ascension Providence Health SystemWashingtonDistrict of ColumbiaUnited States20017
9Alliance for Multispecialty ResearchCoral GablesFloridaUnited States33134-4321
10Research Centers of AmericaHollywoodFloridaUnited States33024
11AppleMed Research IncMiamiFloridaUnited States33155
12Elixia COVID-19Palm BeachFloridaUnited States33410
13Precision Clinical ResearchSunriseFloridaUnited States33351
14Meridian Clinical ResearchSavannahGeorgiaUnited States31406
15ASR, LLCNampaIdahoUnited States83687
16Affinity HealthChicagoIllinoisUnited States60644
17Meridian Clinical ResearchSioux CityIowaUnited States51106
18Benchmark ResearchCovingtonLouisianaUnited States70433
19Ascension St. John Vaccine Research UnitGrosse Pointe WoodsMichiganUnited States48236
20Methodist PhysiciansFremontNebraskaUnited States68130
21Be Well Clinical Studies, LLCLincolnNebraskaUnited States68516
22Meridian Clinical Research LLCNorfolkNebraskaUnited States68701
23Meridian Clinical Research LLCOmahaNebraskaUnited States68134
24Forte Family Practice/ CCT ResearchLas VegasNevadaUnited States89103
25Excel Clinical ResearchLas VegasNevadaUnited States89109
26Las Vegas Clinical TrialsNorth Las VegasNevadaUnited States89030
27Hassman Research InstituteBerlinNew JerseyUnited States08009
28Meridian Clinical ResearchEndwellNew YorkUnited States13760
29Carolina Institute for Clinical ResearchFayettevilleNorth CarolinaUnited States28303
30M3 Wake Research, IncRaleighNorth CarolinaUnited States27612
31Trial Management Associates LLCWilmingtonNorth CarolinaUnited States28403
32Velocity Clinical Research - CincinnatiCincinnatiOhioUnited States45242
33Velocity Clinical ResearchClevelandOhioUnited States44122
34Aventiv Research IncColumbusOhioUnited States43213
35Velocity Clinical Research ProvidenceWarwickRhode IslandUnited States02886
36Benchmark ResearchAustinTexasUnited States78705
37Tekton ResearchAustinTexasUnited States78745
38Global Medical ResearchDallasTexasUnited States75224
39Benchmark ResearchFort WorthTexasUnited States76135
40Research Your HealthPlanoTexasUnited States75093
41Mt. Olympus Medical Research, LLCSugar LandTexasUnited States77479
42Sugar Lakes Family PracticeSugar LandTexasUnited States77479
43DM Clinical Research/Martin Diagnostic ClinicTomballTexasUnited States77375
44South Ogden Family MedicineOgdenUtahUnited States84405
45Advanced Clinical Research, Inc.West JordanUtahUnited States84088
46Mautalen Salud e Investigación (Expertia SA)Buenos AiresArgentinaC1128AAF
47Fundación FunDaMosBuenos AiresArgentinaC1405BOA
48Hospital Militar Central Cirujano Mayor Dr. Cosme ArgerichBuenos AiresArgentinaC1426
49Sanatorio AllendeCórdobaArgentina5000
50Clinica Mayo de UMCB SRLSan Miguel De TucumánArgentinaT4000
51Instituto de Pesquisas Clinicas L2IPBrasíliaBrazil70200-730
52Unidade Hospital do RocioCampo LargoBrazil83606-177
53Santa Casa De Misericordia De Belo HorizonteMinas GeraisBrazil30150-221
54Centro de Pesquisa Clinica - Hospital Moinhos de VentoPorto AlegreBrazil90035-001
55IBPClin Instituto Brasil de Pequisa ClinicaRio De JaneiroBrazil20241-180
56Fundação Faculdade Regional de Medicina de Sao Jose do Rio PretoSão PauloBrazil15090-000
57Azidus Brasil Pesquisa e Desenvolvimento LtdaValinhosBrazil13271-130
58CARe ClinicRed DeerAlbertaCanadaT4N 6V7
59IWK Health Centre- Dalhousie University-Canadian Center for VaccinologyHalifaxNova ScotiaCanadaB3K 6R8
60Aggarwal and Associates LtdBramptonOntarioCanadaL6T 0G1
61Dawson Clinical Research Inc.GuelphOntarioCanadaN1H 1B1
62SKDS Research Inc.NewmarketOntarioCanadaL3Y 5G8
63LMC Clinical Research Inc. (CPU)TorontoOntarioCanadaM4G 3E8
64Manna Research TorontoTorontoOntarioCanadaM9W 4L6
65Manna Research (Quebec)LévisQuebecCanadaG6W OM5
66Manna Research (Mirabel)MirabelQuebecCanadaJ7J 2K8
67McGill University Health Centre Vaccine Study CentrePierrefondsQuebecCanadaH9H 4Y6
68CHU de Québec-Université LavalQuébec CityQuebecCanadaG1E 7G9
69Diex Research Quebec Inc.QuébecQuebecCanadaG1N 4V3
70Diex Recherche JolietteSaint-Charles-BorroméeQuebecCanadaJ6E 2B4
71Q&T Research Sherbrooke Inc.SherbrookeQuebecCanadaJ1J 2G2
72Diex Recherche SherbrookeSherbrookeQuebecCanadaJ1L 0H8
73Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V.AguascalientesMexico20010
74RM Pharma Specialists S.A. de C.V.Ciudad de MéxicoMexico3100
75Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C.CuliacánMexico80230
76Centro Multidisciplinario para el Desarrollo Especializado de la Investigación Clínica en Yucatan S.C.P. (CEMDEICY S.C.P.)MéridaMexico97130
77Integra RGH Centro de Investigacion, Clinica de Ozonoterapia RGH ACPueblaMexico72410
78Sociedad de Metabolismo y Corazon S.C (SOMECO)VeracruzMexico91900
79Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V.ZapopanMexico45070
80NHS GrampianAberdeenUnited KingdomAB25 2ZD
81Synexus Midlands Clinical Research CentreBirminghamUnited KingdomB15 2SQ
82University Hospital Southampton NHS Foundation Trust (UHS)BournemouthUnited KingdomBH7 7DW
83Public Health WalesCardiffUnited KingdomCF10 4BZ
84Synexus Wales DRSCardiffUnited KingdomCF15 9SS
85Mid and South Essex NHS Foundation TrustChelmsfordUnited KingdomCM17ET
86Synexus Lancashire DRSChorleyUnited KingdomPR7 7 NA
87University Hospitals Derby and BurtonDerbyUnited KingdomDE22 3NE
88London North West University Healthcare NHS TrustHarrowUnited KingdomHA1 3UJ
89Kings College HospitalLondonUnited KingdomSE5 9PJ
90Synexus Manchester DRSManchesterUnited KingdomM15 6SE
91University of York/York Teaching HospitalYorkUnited KingdomYO31 8HE

Sponsors and Collaborators

  • Medicago

Investigators

  • Study Director: Brian Ward, MD, Medicago

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Medicago
ClinicalTrials.gov Identifier:
NCT04636697
Other Study ID Numbers:
  • CP-PRO-CoVLP-021
  • NCT04662697
First Posted:
Nov 19, 2020
Last Update Posted:
Sep 9, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 9, 2021